Teva Pharmaceutical Industries (TEVA) FCF Margin (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly FCF Margin of 5.22% for Q1 2026, up 74.0% year-on-year from 3.0% in Q1 2025, and down 124.22% on a QoQ basis from 21.57% in Q4 2025.
Teva Pharmaceutical Industries (TEVA) FCF Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported FCF Margin for 18 consecutive years, with 5.22% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin rose 74.0% year-over-year to 5.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.76% (up 175.0% YoY) and the FY2025 annual result came in at 6.65%, up 212.0% from the prior year.
- FCF Margin declined to 5.22% in Q1 2026 per TEVA's latest filing, from 21.57% in the prior quarter.
- Over the last five years, FCF Margin for TEVA reached as high as 23.89% in Q4 2023 and fell as low as 7.76% in Q1 2023.
- A 5-year average of 5.02% and a median of 3.14% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 1545 bps — and 2024, when it surged 1632 bps.
- Year by year, FCF Margin stood at 21.4% in 2022, then rose by 12 bps to 23.89% in 2023, then plunged by 36 bps to 15.38% in 2024, then soared by 40 bps to 21.57% in 2025, then plunged by 124 bps to 5.22% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 5.22%, 21.57%, and 5.2% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 1.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.22% |
| Dec 31, 2025 | 21.57% |
| Sep 30, 2025 | 5.20% |
| Jun 30, 2025 | 3.14% |
| Mar 31, 2025 | -5.96% |
| Dec 31, 2024 | 15.38% |
| Sep 30, 2024 | 12.58% |
| Jun 30, 2024 | 0.14% |
| Mar 31, 2024 | -6.49% |
| Dec 31, 2023 | 23.89% |
| Sep 30, 2023 | -3.74% |
| Jun 30, 2023 | 5.29% |
| Mar 31, 2023 | -7.76% |
| Dec 31, 2022 | 21.40% |
| Sep 30, 2022 | 11.71% |
| Jun 30, 2022 | -0.11% |
| Mar 31, 2022 | -5.63% |
| Dec 31, 2021 | 7.39% |
| Sep 30, 2021 | 9.85% |
| Jun 30, 2021 | 2.69% |